Q4 2018 EPS Estimates for PRA Health Sciences Inc Increased by Analyst (PRAH)

PRA Health Sciences Inc (NASDAQ:PRAH) – Stock analysts at Mitsubishi UFJ Financial Group boosted their Q4 2018 EPS estimates for shares of PRA Health Sciences in a note issued to investors on Thursday, November 1st. Mitsubishi UFJ Financial Group analyst J. Twizell now anticipates that the medical research company will post earnings per share of $1.18 for the quarter, up from their prior estimate of $1.16. Mitsubishi UFJ Financial Group also issued estimates for PRA Health Sciences’ Q1 2019 earnings at $0.88 EPS and Q4 2019 earnings at $1.37 EPS.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The business had revenue of $717.60 million for the quarter, compared to analysts’ expectations of $729.63 million. During the same period in the previous year, the business posted $0.88 EPS. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year.

A number of other equities research analysts have also recently issued reports on the company. SunTrust Banks boosted their price objective on PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research note on Monday. BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. UBS Group assumed coverage on PRA Health Sciences in a research report on Tuesday, October 9th. They set a “neutral” rating on the stock. Evercore ISI assumed coverage on PRA Health Sciences in a research report on Thursday, October 4th. They set an “inline” rating and a $120.00 price target on the stock. Finally, Robert W. Baird upped their price target on PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Tuesday, September 11th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $111.50.

Shares of PRA Health Sciences stock opened at $102.49 on Monday. PRA Health Sciences has a 52-week low of $76.39 and a 52-week high of $112.88. The stock has a market capitalization of $6.47 billion, a P/E ratio of 32.03, a PEG ratio of 1.47 and a beta of 0.73. The company has a current ratio of 0.89, a quick ratio of 0.93 and a debt-to-equity ratio of 1.22.

Several hedge funds and other institutional investors have recently modified their holdings of PRAH. Allianz Asset Management GmbH grew its holdings in shares of PRA Health Sciences by 18.0% during the first quarter. Allianz Asset Management GmbH now owns 319,330 shares of the medical research company’s stock worth $26,491,000 after purchasing an additional 48,660 shares in the last quarter. Bellecapital International Ltd. grew its holdings in shares of PRA Health Sciences by 32.9% during the second quarter. Bellecapital International Ltd. now owns 65,730 shares of the medical research company’s stock worth $6,137,000 after purchasing an additional 16,270 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in shares of PRA Health Sciences during the second quarter worth about $572,000. First National Bank of Hutchinson purchased a new position in shares of PRA Health Sciences during the second quarter worth about $671,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of PRA Health Sciences during the second quarter worth about $411,000. 98.82% of the stock is owned by institutional investors.

In other news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $101.01, for a total transaction of $656,565,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.85% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: What Factors Can Affect Return on Equity?

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply